Taken together, our findings suggest that USP2 stabilizes Mdm2 which antagonizes pro-apoptotic activity of p53 and possibly contributes to therapeutic resistance in CTCL. The gene discussed is USP2; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.